Author + information
- Luca Testa1,
- Sameer Dani2,
- Nirav Bhalani3,
- Arvind Sharma3,
- Chirag Sheth3,
- Prathapkumar Natarajapillai4,
- Apurva Vasavada5,
- Jayachandran Thejus4,
- Pritesh Parekh6,
- Kamal Sharma2 and
- Rutvik Trivedi7
- 1IRCCS Policlinico S. Donato, San Donato M.ne, Milan, Italy
- 2Apollo Hospitals, Ahmedabad, India
- 3Rhythm Heart Institute, Baroda, Gujarat, India
- 4Meditrina Hospital, Trivandrum, India
- 5Tristar Hospital, Surat, Gujarat, India
- 6Care Hospitals, Surat, Gujarat, India
- 7Zydus Hospitals and Healthcare Research Pvt Ltd, Anand, Gujarat, India
Diabetes Mellitus (DM) remain at high risk of in-stent restenosis and adverse cardiovascular events. We examined the results of Abluminus®DES+, a stent with an abluminal coating on stent and parts of the balloon with sirolimus in the cohort of diabetic patients.
Of 1,841 patients treated for coronary artery disease, 682 patients had diabetes and were treated with 908 Abluminus®DES+ stents. The primary end point, Major Adverse Cardiac Event (MACE), was a composite of cardiac death, Target Vessel-Myocardial Infarction (TV-MI) and Target Lesion Revascularization (TLR)/Target Vessel Revascularization (TVR) within 1 year. The secondary end point was Stent Thrombosis (ST) and MACE within 2 years.
814 lesions in 682 patients were included in the cohort of diabetic patients. The average age was 57.68 ± 9.63 years. 77.57% were male. 80% were T2DM and 60.26% had hypertension. The main indication for the angiogram was acute coronary syndrome (58.21%). Almost half of patients had type B/C lesions. 1.43 stents were implanted per patient. The incidence of MACE in 81.38% (555/682 patients) who completed 1 year the follow-up was 2.88% (cardiac death 0.18%, TV-MI 0.54%, TLR/TVR was 2.16% respectively). The incidence of ST was 0.72% and all of them were acute ST. At 2 year, 57.62% completed follow-up with an increment of MACE in only one patient. The follow-up is ongoing in remaining patients.
This study gives the insight into the impact diabetes mellitus on clinical outcome in patients treated with the novel Abluminus® DES+ stent. At 1 year after a stent placement very low incidence of MACE and ST were observed.